COMP <GO>
PTCT vs LLY // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
PTC Therapeutics Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: PTCT 8
— LLY 4
■ METRIC PARITY
LAST: $64.46 (+2.29%) • MKT CAP: $5.38B
options-implied-move
—
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
options-implied-move
6.77%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PTCT VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PTCT | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 83.64% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 32.36% | +52.64 | PTCT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.5x | 36.4x | -29.92 | PTCT | /valuation <GO> |
| Free Cash Flow Yield | 13.05% | 2.30% | +10.75 | PTCT | /fcf-yield <GO> |
| Operating Margin | 50.10% | 40.21% | +9.89 | PTCT | /operating-margins <GO> |
| Net Profit Margin | 39.50% | 31.90% | +7.60 | PTCT | /net-margins <GO> |
| Revenue Growth (YoY) | 114.50% | 45.51% | +68.99 | PTCT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.73 | 9.29 | -7.56 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.0 | 66.6 | -13.60 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.51 | +0.64 | PTCT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.6x | 26.3x | -19.65 | PTCT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.38B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PTCT REV | LLY REV | PTCT GROSS % | LLY GROSS % | PTCT FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.73B | $65.18B | — | 83.0% | $702.3M | $16.81B |
| FY 2024 | $806.8M | $45.04B | — | 81.3% | -$114.2M | $8.82B |
| FY 2023 | $937.8M | $34.12B | — | 79.3% | -$200.6M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PTCT // BETA 1.15
LLY // BETA 0.51